PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy

Clinical trial NCT05676697 · TERMINATED

Trial details

NCT number: NCT05676697
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Autoimmune Hemolytic Anemia Failure of Two Rounds of Treatment

Start date: 2023-01-13
Primary completion: 2024-01-31
Enrollment: 4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.